Findings

What do systematic reviews say?

10 questions · 10 findings · 5 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 40%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 20%Moderate 4 · 40%High 0 · 0%

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

All‐cause mortality (7 months) · participants with diagnosed DVT

Oral DTIs showed no clear difference in all‐cause mortality (7 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.66 [0.41, 1.08]
1 study · 2489 participants
Moderate

Avoralstat vs placebo

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral factor Xa inhibitors vs conventional anticoagulation

All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 1.16 [0.79, 1.7]
1 study · 4817 participants
Moderate

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques

The review found no eligible studies for this question.

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral factor Xa inhibitors vs conventional anticoagulation

All‐cause mortality (3 to 6 months) · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.87 [0.67, 1.14]
9 studies · 10770 participants
Moderate

Totally percutaneous vs cut‐down femoral artery access

Short‐term mortality (30‐day or in‐hospital) · people undergoing elective bifurcated abdominal endovascular aneurysm repair

Totally percutaneous showed no clear difference in short‐term mortality (30‐day or in‐hospital) compared with cut‐down femoral artery access (low certainty).

1 finding from 1 review

Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal endovascular… 2023 · Cochrane Headline outcomes only
RR 1.5 [0.06, 36.18]
2 studies · 181 participants
Low

Extended prophylaxis vs another VTE extended prophylaxis

All‐cause mortalitye · patients with unprovoked venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Extended prophylaxis vs placebo

All‐cause mortalityg · patients with unprovoked venous thromboembolism

Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
OR 1 [0.63, 1.57]
5 studies · 2043 participants
Moderate

Extended prophylaxis vs placebo

VTE‐related mortality4 · patients with unprovoked venous thromboembolism

Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
OR 0.98 [0.14, 6.98]
4 studies · 1862 participants
Low

Extended prophylaxis vs another VTE extended prophylaxis

VTE‐related mortality4 · patients with unprovoked venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found